DK3598971T3 - Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin - Google Patents

Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin Download PDF

Info

Publication number: DK3598971T3
Authority: DK; Denmark
Prior art keywords: chlorokynurenine; dosage forms; therapeutic uses; therapeutic; dosage
Prior art date: 2013-01-22

Application number

DK19196366.9T

Other languages

English (en)

Inventor

Ralph H Snodgrass

Allen E Cato

Jack S Hicklin

Original Assignee

Vistagen Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-22

Filing date

2014-01-22

Publication date

2024-06-10

2014-01-22 Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc

2024-06-10 Application granted granted Critical

2024-06-10 Publication of DK3598971T3 publication Critical patent/DK3598971T3/da

Links

HQLHZNDJQSRKDT-QMMMGPOBSA-N (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=C(Cl)C=C1N HQLHZNDJQSRKDT-QMMMGPOBSA-N 0.000 title 1
239000002552 dosage form Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Lubricants (AREA)
Quinoline Compounds (AREA)

DK19196366.9T 2013-01-22 2014-01-22 Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin DK3598971T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361849191P	2013-01-22	2013-01-22
EP17170079.2A EP3228313B1 (en)	2013-01-22	2014-01-22	Dosage forms and therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number	Publication Date
DK3598971T3 true DK3598971T3 (da)	2024-06-10

Family

ID=51228003

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK17170079T DK3228313T3 (da)	2013-01-22	2014-01-22	Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin
DK19196366.9T DK3598971T3 (da)	2013-01-22	2014-01-22	Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin
DK14743570.5T DK2948140T3 (da)	2013-01-22	2014-01-22	Doseringsformer og terapeutiske anvendelser af l-4-chlorkynurenin

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK17170079T DK3228313T3 (da)	2013-01-22	2014-01-22	Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK14743570.5T DK2948140T3 (da)	2013-01-22	2014-01-22	Doseringsformer og terapeutiske anvendelser af l-4-chlorkynurenin

Country Status (21)

Country	Link
US (7)	US9993450B2 (da)
EP (4)	EP2948140B1 (da)
JP (5)	JP6436913B2 (da)
KR (5)	KR20230098711A (da)
CN (4)	CN105073108A (da)
AU (4)	AU2014209466B2 (da)
BR (1)	BR112015017535A2 (da)
CA (3)	CA3216579A1 (da)
CY (1)	CY1122403T1 (da)
DK (3)	DK3228313T3 (da)
ES (2)	ES2635353T3 (da)
HK (1)	HK1217170A1 (da)
HR (1)	HRP20192189T1 (da)
IL (3)	IL291831A (da)
MX (2)	MX2015009277A (da)
PL (1)	PL3228313T3 (da)
PT (2)	PT2948140T (da)
RS (1)	RS59687B1 (da)
SI (1)	SI3228313T1 (da)
WO (1)	WO2014116739A1 (da)
ZA (2)	ZA201505569B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6436913B2 (ja)	2013-01-22	2018-12-12	ヴィスタゲンセラピューティクス、インコーポレイテッド	Ｌ−４−クロロキヌレニンの剤形及び治療的使用
AU2016268153B2 (en) *	2015-05-22	2021-08-12	Vistagen Therapeutics, Inc.	Therapeutic uses of L-4-chlorokynurenine
EP3347346A1 (en) *	2015-09-08	2018-07-18	Cephalon, Inc.	Prodrugs of chlorokynurenines
JP7431163B2 (ja)	2018-02-09	2024-02-14	ヴィスタゲンセラピューティクス、インコーポレイテッド	４－クロロキヌレニンおよび中間体の合成
CN109223785A (zh) *	2018-10-29	2019-01-18	中国药科大学	犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
WO2022082100A1 (en) *	2020-10-16	2022-04-21	Vistagen Therapeutics, Inc.	Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5086072A (en) *	1990-06-18	1992-02-04	The United States Of America As Represented By The Department Of Health And Human Services	Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5360814A (en)	1991-02-28	1994-11-01	Merrell Dow Pharmaceuticals Inc.	NMDA antagonists
US5484814A (en)	1991-02-28	1996-01-16	Merrell Dow Pharmaceuticals Inc.	NMDA antagonists
US5763393A (en)	1996-05-17	1998-06-09	Neurotherapeutics L.P.	Neuroactive peptides
TW518218B (en)	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1427404A4 (en)	2001-08-20	2005-10-26	Maiken Nedergaard	TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS
EP1545551A4 (en)	2002-09-06	2008-10-22	Durect Corp	DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
US20060063802A1 (en)	2004-03-29	2006-03-23	Matthieu Guitton	Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2009533393A (ja)	2006-04-12	2009-09-17	プロビオドルグエージー	酵素阻害薬
EP1903028A1 (en) *	2006-09-22	2008-03-26	Werner Tschollar	Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects
US8058243B2 (en)	2006-10-13	2011-11-15	Hsc Research And Development Limited Partnership	Method for treating a brain cancer with ifenprodil
ES2533484T3 (es)	2007-04-18	2015-04-10	Probiodrug Ag	Derivados de tiourea como inhibidores de la glutaminil ciclasa
WO2009135091A1 (en) *	2008-04-30	2009-11-05	Medivation Technologies, Inc.	Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20100048629A1 (en) *	2008-08-21	2010-02-25	Allyson Gage	Methods for treating neuropathic pain
WO2010121973A1 (en)	2009-04-23	2010-10-28	Universität Zürich	Blockers of nmda receptor for the treatment of sickle cell anemia
JPWO2011019072A1 (ja)	2009-08-12	2013-01-17	ヒューマン・メタボローム・テクノロジーズ株式会社	うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
AU2011267474B2 (en) *	2010-06-15	2016-05-26	Grünenthal GmbH	Pharmaceutical combination for the treatment of pain
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
JP6436913B2 (ja)	2013-01-22	2018-12-12	ヴィスタゲンセラピューティクス、インコーポレイテッド	Ｌ−４−クロロキヌレニンの剤形及び治療的使用
WO2014152835A1 (en)	2013-03-14	2014-09-25	Vistagen Therapeutics, Inc.	Synthesis of chiral kynurenine compounds and intermediates
AU2014342624A1 (en)	2013-10-28	2016-06-02	Naurex, Inc.	NMDA receptor modulators and prodrugs, salts, and uses thereof
AU2016268153B2 (en)	2015-05-22	2021-08-12	Vistagen Therapeutics, Inc.	Therapeutic uses of L-4-chlorokynurenine

2014
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 MX MX2015009277A patent/MX2015009277A/es active IP Right Grant
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en active Application Filing
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/da active
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 EP EP24164414.5A patent/EP4385563A2/en active Pending
- 2014-01-22 IL IL291831A patent/IL291831A/en unknown
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Application Discontinuation
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active IP Right Grant
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Application Discontinuation
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 BR BR112015017535A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Application Discontinuation
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active IP Right Grant
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-05-05 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-06-21 US US17/845,105 patent/US20220409564A1/en active Pending
- 2022-08-22 AU AU2022221382A patent/AU2022221382A1/en active Pending
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending

Also Published As

Publication number	Publication date
KR20210063449A (ko)	2021-06-01
CN113116877A (zh)	2021-07-16
EP2948140A1 (en)	2015-12-02
KR20230098711A (ko)	2023-07-04
US20220409564A1 (en)	2022-12-29
PL3228313T3 (pl)	2020-03-31
DK2948140T3 (da)	2017-08-21
IL276126A (en)	2020-08-31
RS59687B1 (sr)	2020-01-31
KR102257284B1 (ko)	2021-05-28
EP2948140A4 (en)	2016-08-03
US10617663B2 (en)	2020-04-14
CY1122403T1 (el)	2021-01-27
JP2024069257A (ja)	2024-05-21
KR20210149905A (ko)	2021-12-09
SI3228313T1 (sl)	2019-12-31
EP2948140B1 (en)	2017-05-10
US20160158178A1 (en)	2016-06-09
CA2898619A1 (en)	2014-07-31
JP2022070894A (ja)	2022-05-13
EP3228313B1 (en)	2019-09-11
BR112015017535A2 (pt)	2020-02-04
JP7021298B2 (ja)	2022-02-16
EP3598971B1 (en)	2024-03-20
JP2016505050A (ja)	2016-02-18
US10980758B2 (en)	2021-04-20
PT2948140T (pt)	2017-08-10
US10632091B2 (en)	2020-04-28
PT3228313T (pt)	2019-12-17
AU2018253600B2 (en)	2020-07-09
AU2014209466B2 (en)	2018-11-08
ES2635353T3 (es)	2017-10-03
JP2019023195A (ja)	2019-02-14
IL276126B (en)	2022-05-01
US20180369180A1 (en)	2018-12-27
CA2898619C (en)	2021-10-19
AU2022221382A1 (en)	2022-09-15
CN105073108A (zh)	2015-11-18
EP3598971A1 (en)	2020-01-29
MX2020009966A (es)	2020-10-12
JP6436913B2 (ja)	2018-12-12
ES2751138T3 (es)	2020-03-30
US20150359772A1 (en)	2015-12-17
CN113209068A (zh)	2021-08-06
JP2020183400A (ja)	2020-11-12
IL240090B (en)	2020-08-31
AU2018253600A1 (en)	2018-11-22
ZA201607581B (en)	2019-04-24
KR20230003410A (ko)	2023-01-05
CA3216579A1 (en)	2014-07-31
AU2014209466A1 (en)	2015-08-06
MX2015009277A (es)	2015-12-11
EP4385563A2 (en)	2024-06-19
IL240090A0 (en)	2015-09-24
AU2020204420A1 (en)	2020-07-23
EP3228313A1 (en)	2017-10-11
US9993450B2 (en)	2018-06-12
CN112933073A (zh)	2021-06-11
IL291831A (en)	2022-06-01
DK3228313T3 (da)	2019-11-25
NZ710121A (en)	2021-01-29
US9993453B2 (en)	2018-06-12
JP6804497B2 (ja)	2020-12-23
KR20150109428A (ko)	2015-10-01
US20190133984A1 (en)	2019-05-09
ZA201505569B (en)	2017-01-25
HK1217170A1 (zh)	2016-12-30
CA3128321A1 (en)	2014-07-31
KR102335919B1 (ko)	2021-12-07
US20180289649A1 (en)	2018-10-11
US20190125707A1 (en)	2019-05-02
CA3128321C (en)	2023-12-05
HRP20192189T1 (hr)	2020-02-21
WO2014116739A1 (en)	2014-07-31

Publication	Publication Date	Title
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
DK2968443T3 (da)	2021-12-06	Hepcidinanaloger og anvendelser deraf
DK3080100T3 (da)	2023-02-06	Hæmmere af lysinspecifik demethylase-1
DK3035955T3 (da)	2019-12-02	Sammensætning og vaccine til behandling af lungekræft
DK3019483T3 (da)	2020-02-24	Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse
DK3121164T3 (da)	2020-05-11	Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
DK2958588T3 (da)	2017-11-20	Kombination af vaccination og hæmning af PD-1-reaktionsvejen
DK3021838T3 (da)	2020-08-24	Behandling af fedme
DK2961388T3 (da)	2019-07-08	Kombinationer af lægemidler
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3076972T3 (da)	2022-01-03	Cancerbehandling med kombination af plinabulin og taxan
DK2882441T3 (da)	2020-05-25	Behandling af immunrelaterede og inflammatoriske sygdomme
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3626270T3 (da)	2024-01-15	Behandling af kardiovaskulære sygdomme
DK2964255T3 (da)	2021-02-08	Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK2981541T3 (da)	2017-11-13	Syntese og anvendelse af isotopmærkede glycaner
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3082902T3 (da)	2019-12-16	Kropsbåret injektor og anvendelsesmetode
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf
DK3003306T3 (da)	2020-11-30	Gentagen indgivelse af ikke-immunosupressive antigenspecifikke immunterapeutika
DK2767269T3 (da)	2019-05-06	Terapeutisk anordning